Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naïve Prostate Cancer

NCT01302041 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01302041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01302041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naïve Prostate Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2011
Completion date
April 27, 2017
Enrollment
67 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer